This is a working overview of 垂体受体, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-06. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
nuclear magnetic resonance spectroscopy A technique that exploits the magnetic properties of certain atomic nuclei, useful for identifying unknown compounds. Nuclear magnetic resonance is often abbreviated NMR.
18 September – A study published in Nature Neuroscience, using mouse embryos and human pluripotent stem cells, finds that the forebrain and midbrain develop from a different progenitor cell lineage from the hindbrain, challenging the long-standing model of a single progenitor population for the entire brain. The authors propose that the brain is a composite organ arising from two developmentally distinct systems that may have been evolutionarily conserved for more than 550 million years.
As the complexity of proteolytic networks was uncovered, more thorough descriptions of the degradome and ways to study it became necessary. In 2007, Dr. Overall updated the field with a review co-authored by Dr. Carl Blobel detailing how advanced methods were revolutionizing protease-substrate discovery. They described the process of linking proteases to their substrates on a step by step process, beginning with biochemical and proteomic discovery, validation using cellular based assays, and progressing to whole organism levels using animal models. More recently, as technology and techniques have advanced, the Overall Lab and others have continued to direct the field using more powerful and quantitative techniques.
==== Response and fallout ==== Although the experimental protocol had not been published, physicists in several countries attempted, and failed, to replicate the excess heat phenomenon. The first paper submitted to Nature reproducing excess heat, although it passed peer review, was rejected because most similar experiments were negative and there were no theories that could explain a positive result; this paper was later accepted for publication by the journal Fusion Technology. Nathan Lewis, professor of chemistry at the California Institute of Technology, led one of the most ambitious validation efforts, trying many variations on the experiment without success, while CERN physicist Douglas R. O. Morrison said that "essentially all" attempts in Western Europe had failed. Even those reporting success had difficulty reproducing Fleischmann and Pons' results. On 10 April 1989, a group at Texas A&M University published results of excess heat and later that day a group at the Georgia Institute of Technology announced neutron production—the strongest replication announced up to that point due to the detection of neutrons and the reputation of the lab. On 12 April Pons was acclaimed at an ACS meeting. But Georgia Tech retracted their announcement on 13 April, explaining that their neutron detectors gave false positives when exposed to heat. Another attempt at independent replication, headed by Robert Huggins at Stanford University, which also reported early success with a light water control, became the only scientific support for cold fusion in 26 April US Congress hearings.
Emboldened by the footage, Aditya gets reinstated by the police by proving his physical and mental stability. He then traces Ajay's true biological origins to Hari. Attempting to evade Aditya, Hari organises the murders of numerous police officers. Undeterred, Aditya traces Hari's location to an old office building of Mumbai Media that media tycoon Pramod Gupta owns, who is one of Hari's associates. With the help of the police, Aditya launches a raid on the complex. He kills Hari's goons and captures Gupta but fails to capture Hari, who retreats to the site of his earlier massacre and lures Aditya by holding the families of the murdered police officers hostage at gunpoint. Aditya fights with Hari and wins. Hari attempts to shoot Aditya, but he throws a knife at Hari's neck then stabs him repeatedly to death. As Aditya walks out of the police station, a young boy dressed in a police uniform looks at him and salutes with a smile. Aditya returns the smile and salute.
Sources: en.wikipedia.org
== Treatment == Currently, there is no cure for Urbach–Wiethe disease, although there are some ways to individually treat many of its symptoms. There has been some success with oral dimethyl sulfoxide (DMSO) and intralesional heparin, but this is not true in all cases. D-penicillamine has also shown promise, but has yet to have been used extensively. There are also some reports of patients being treated with etretinate, a drug typically prescribed to treat psoriasis. In some cases, calcifications in the brain can lead to abnormal electrical activity among neurons. Some patients are given anti-seizure medication to help deal with these abnormalities. Tracheostomy is often used to relieve upper respiratory tract infections. Carbon dioxide laser surgery of thickened vocal cords and beaded eyelid papules have improved these symptoms for patients. The discovery of the mutations of the ECM1 gene has opened the possibility of gene therapy or a recombinant EMC1 protein for Urbach–Wiethe disease treatment, but neither of these two options are currently available.
== History == In 1999 it became a wholly owned subsidiary of the publicly held Cracker Barrel. On December 6, 2006, Logan's Roadhouse was sold to affiliates of Bruckmann, Rosser, Sherrill & Co., Canyon Capital Advisors LLC, and Black Canyon Capital LLC for $486 million. In 2010, private equity firm Kelso & Company acquired the company. On February 20, 2013, Mike Andres, a former McDonald's vice-president and former chief executive officer of Boston Market, replaced Tom Vogel as chief executive officer. On January 12, 2017, Hazem Ouf, former chief executive officer of American Blue Ribbon Holdings, was named president and chief executive officer. On August 8, 2016, Logan's Roadhouse filed for bankruptcy and announced plans to close eighteen of its 256 locations that are under-performing. The chain was reported to be struggling with heavy debt and falling sales. Locations closing in late September 2016, include, in Florida, two each in Kissimmee and Orlando, and one each in Mary Esther, Tampa, and Tallahassee; one in each of those cities: Macon, Georgia; Houston, Texas; Lafayette, Louisiana and Waynesboro, Virginia. On December 1, 2016, Logan's Roadhouse formally exited bankruptcy with a debt load reduced from about $400 million to $100 million. On November 1, 2018, Logan's Roadhouse announced that it was acquired by CraftWorks Restaurants & Breweries. On March 3, 2020, Craftworks filed for Chapter 11 Bankruptcy protection. On March 19, 2020, all open Logan's locations were temporarily closed amid the COVID-19 pandemic.
NA also promotes cell fusion, which helps the nascent virions to avoid contact with host antibodies and thus enables the virus to spread within tissues. cytotoxic T lymphocytes. Variable sialidases can cause this effect, including NA from Newcastle disease virus that have been shown to cleave 2,3-, 2,6-, and 2,8-linkages between sialic acid residues. In vitro, there was no significant difference between NAs from Newcastle disease virus, SeV and mumps virus with respect to substrate specificity. These results suggest that treating a tumor with the virus results in desialylation of malignant cells, which contributes to increased anti-tumor immune surveillance. Therefore, the ability of SeV sialidase (NA) to remove sialic acid from the surface of malignant cells most likely helps to ensure the availability of tumor antigens for recognition by cytotoxic T lymphocytes.
=== Acute === Acute inflammation is a short-term process, usually appearing within a few minutes or hours and beginning to cease upon the removal of the injurious stimulus. It involves a coordinated and systemic mobilization response of various immune, endocrine and neurological mediators of acute inflammation. In a normal healthy response, it becomes activated, clears the pathogen and begins a repair process and then ceases. Acute inflammation occurs immediately upon injury, lasting only a few days. Cytokines and chemokines promote the migration of neutrophils and macrophages to the site of inflammation. Pathogens, allergens, toxins, burns, and frostbite are some of the typical causes of acute inflammation. Toll-like receptors (TLRs) recognize microbial pathogens. Acute inflammation can be a defensive mechanism to protect tissues against injury. Inflammation lasting 2–6 weeks is designated subacute inflammation.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.